Representatively, lung cancer harboring EGFR mutations is generally not considered for treatment with ICIs given that multiple clinical trials have found that ICIs provide limited survival benefit for this particular population (26), whereas KRAS mutation is a favorable biomarker for ICIs benefit (39). Here, KRAS is linked to lung carcinoma.